Open access
Open access
Powered by Google Translator Translator

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.

16 Nov, 2021 | 08:14h | UTC

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases – The University of Texas MD Anderson Cancer Center

Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases

Related: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 


Stay Updated in Your Specialty

No spam, just news.